- Preliminary Q3 2026 GAAP and adjusted EPS include $0.11/share charge from $216M IPR&D expense.
- Q3 adjusted EPS guidance: $3.73-$3.77.
- Full-year 2026 adjusted EPS guidance: $13.76-$13.96.
- Company does not forecast future IPR&D expense; full-year guidance excludes any beyond Q3 2026.
- AbbVie disclosed in an SEC filing that its preliminary Q3 2026 results will include $216 million in acquired IPR&D and milestones expense, reducing both GAAP and adjusted diluted EPS by $0.11. The company updated its Q3 adjusted EPS guidance to $3.73-$3.77 and full-year 2026 adjusted EPS guidance to $13.76-$13.96 to reflect the charge.
The headline and the read are open. The reasons are one free account away, on every story.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
BORSAPLUSWhy it matters · Bull and bear case · Reaction against SPY and the sector · What to watch
Create a free account · no card